iFR Co-registration
Elevate your physiologic decision-making with iFR Co-registration
Only Philips iFR Co-registration helps you decide where to treat by mapping the iFR pull back directly onto the angiogram for a new dimension in PCI guidance.
Demonstrated results
1 in 4
patients with an angiographically successful PCI left the cath lab with residual ischemia (defined as iFR <0.90 residual DS <50% in any treated lesion).1
81.6%
of patients with residual ischemia, were caused by an untreated angiographically inapparent physiologically focal stenosis (≤ 15 mm).1
79%
reduction in residual ischemia if all focal lesions had been successfully treated (24% to 5%).1
68%
relative reduction in clinical events at 1 year follow-up among patients achieving post-PCI iFR ≥ 0.95 (p-value=0.04).2
Features
Virtually plan your PCI and predict results
Angiography provides a visual picture, but often lacks the detail needed for optimal PCI planning. Only Philips provides advanced physiologic guidance to help you determine not just whether to treat, but also where to treat, ensuring precise, patient-focused care.
Get advanced physiologic insight
Quickly and easily understand lesion-specific physiology
Quick iFR Co-registration graphically displays the iFR drop along the angiogram, highlighting which portion of the vessel is ischemic.
Make length measurements without a cumbersome pull back device
iFR Co-registration is calibrated for distance, so with a simple manual pullback you can make measurements on the angiogram and trend line.
iFR and IVUS Tri-registration
Obtain easy measurements that combine IVUS and iFR information with the angiogram to help determine if a stent will meet the procedural objectives.
World’s first solid core pressure guide wire.7
With an all new workhorse design, only Philips OmniWire pressure wire combines confidence in wire performance with proven fire outcomes and iFR Co-registration, making it easy to benefit from physiology throughout the case.1, 5-6
Philips iFR Co-registration technology is available on
-
IntraSight
The IntraSight applications platform is where imaging, physiology, co-registration* and software all come together to clearly identify coronary and peripheral artery disease, and allow for more optimized treatment plans. IntraSight is built on a new foundational platform designed to meet the evolving needs of your lab today and tomorrow.
IGTDINTRSGHT -
SyncVision
The SyncVision precision guidance system is suitable with IntraSight and Core Integrated interventional platforms and streamlines lesion assessment, simplifies vessel sizing and enables precise therapy delivery all while integrating seamlessly in daily workflows in interventional suites of choice.
IGTDSYNC
Documentation
- Video assets
-
Footnotes
[1] Jeremias A, et al. Blinded Physiological Assessment of Residual Ischemia After Successful Angiographic Percutaneous Coronary Intervention: The DEFINE PCI Study. JACC Cardiovasc Interv. 2019;12(20):1991-2001. [2] Patel M., et al. 1-Year outcomes of blinded physiological assessment of residual ischemia after successful PCI. JACC Cardiol Interv. 2022;15(1):52-61. [3] Joseph T, Foley M, Al-Lamee R. Physiology and Intravascular Imaging Coregistration—Best of all Worlds? Intervent Cardiol Clin 2023;12:71–82. [4] Matsuo A, Kasahara T, Ariyoshi M, et al. Utility of angiography–physiology coregistration maps during percutaneous coronary intervention in clinical practice. Cardiovasc Interv Ther 2021;36(2):208–18.
[5] Davies JE, et al., Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.
[6] Gotberg M, et al., iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.
[7] Data on file D000410086_A, D000485394_A
